Home › Research › Biomarkers
Plasma Biomarker Profiles in a Colombian Cohort of Heterozygous APOE3-Christchurch Carriers
Malotaux V, Tristão-Pereira C, Zuluaga Y, Munoz C, Guerrero A, Bocanegra Y, Alzate D, Serna L et al.. Research Square, 2026-08-18
Topic: Genetics and APOE
Plain-language summary
Objectives To determine whether the rare APOE3 Christchurch (APOE3 Ch ) variant, known to delay clinical onset in PSEN1 E280A -associated autosomal-dominant Alzheimer's disease (ADAD), also attenuates age-related changes in plasma biomarkers of neurodegeneration and neuroinflammation. Methods In this cross-sectional study, plasma Aβ42/40, phosphorylated tau 181 (p-tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) were quantified in 134 members of the Colombian PSEN1 E280A kindred, including eight heterozygous APOE3 Ch -PSEN1 E280A carriers and 14 APOE3 Ch -only carriers. Results APOE3 Ch heterozygosity was associated with significantly attenuated age-related increases in GFAP (f²=0.247), p-tau181 (f²=0.133), and NfL (f²=0.133) among PSEN1 E280A carriers. No significant effect was observed for Aβ42/40, nor among non-carriers. Elevated GFAP and NfL concentrations correlated with poorer memory performance in mutation carriers. Discussion APOE3 Ch -associated resilience is measurably reflected in plasma biomarker trajectories, indicating attenuation of both neuroinflammatory and neurodegenerative processes. Plasma GFAP, p-tau181, and NfL emerge as candidate pharmacodynamic markers for clinical trials targeting APOE3 Ch -mediated mechanisms. These findings open a new avenue for monitoring resilience-based therapeutic strategies in ADAD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Malotaux, V., Tristão-Pereira, C., Zuluaga, Y., Munoz, C., Guerrero, A., Bocanegra, Y., et al. (2026). Plasma Biomarker Profiles in a Colombian Cohort of Heterozygous APOE3-Christchurch Carriers. Research Square. https://doi.org/10.21203/rs.3.rs-10705602/v1
Vancouver
Malotaux V, Tristão-Pereira C, Zuluaga Y, Munoz C, Guerrero A, Bocanegra Y, et al. Plasma Biomarker Profiles in a Colombian Cohort of Heterozygous APOE3-Christchurch Carriers. Research Square. 2026. doi:10.21203/rs.3.rs-10705602/v1.
BibTeX
@article{malotaux2026-6c38e2c0,
author = {Malotaux, V. and Tristão-Pereira, C. and Zuluaga, Y. and Munoz, C. and Guerrero, A. and Bocanegra, Y. and Alzate, D. and Serna, L. and others},
title = {{Plasma Biomarker Profiles in a Colombian Cohort of Heterozygous APOE3-Christchurch Carriers}},
journal = {Research Square},
year = {2026},
doi = {10.21203/rs.3.rs-10705602/v1},
url = {https://doi.org/10.21203/rs.3.rs-10705602/v1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results APOE3 Ch heterozygosity was associated with significantly attenuated age-related increases in GFAP (f²=0.247), p-tau181 (f²=0.133), and NfL (f²=0.133) among PSEN1 E280A carriers.
- No significant effect was observed for Aβ42/40, nor among non-carriers.
- These findings open a new avenue for monitoring resilience-based therapeutic strategies in ADAD.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 27 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 17 of the 62 points we could judge it on, which is 27 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (Research Square) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 17 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 17 of the 62 points we could judge it on is 27 out of 100. |
| Total | 27 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.